Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL-514 Phase 1 for Abdominal Subcutaneous Fat
NCT04699669Phase 1Completed
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Nov 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBL-514 (9 arms), sponsored by Caliway Biopharmaceuticals. Primary endpoints: Incidence of treatment emergent adverse events at 4 weeks, Number of participants with clinically significant abnormalities in clinical laboratory values at 2 weeks and 4 more. Started Nov 2018; status: completed.
02
Drugs
CBL-514
Beyond the preview
Go deeper on NCT04699669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699669.